Session VII: Gastric Cancer: Presentation of selected abstracts

Overall survival results from a Phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
Josep Tabernero, et al., LBA-002

The authors of the study conclude that

" trifluridine/tipiracil (FTD/TPI) showed a meaningful and statistically significant improvement in OS and PFS compared with placebo in heavily pretreated mGC."

-31% reduction in risk of death (HR, 0.69,95%CI 0.56-085; p=0.0003)

- 2.1 months improvement in median OS (5.7 vs. 3.6 months)

FTD/TPI showed a predictable and manageable safety profile, consistent with that seen previously in patients with mCRC

FTD/TPI represents an effective treatment option with a manageable safety profile for patients with heavily pretreated mGC"

See also the subgroup Analysis

See the webcast from this presentation

See statement Josep Tabernero below

See statement Alexander Siebenhüner below

Press Release SERVIER & TAIHO
 
KEYNOTE-061: phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
Kohei Shitara, et al., LBA-005

The authors of the study conclude that "Pembrolizumab did not significantly improve OS vs paclitaxel in patients with previously treated G/GEJ cancer and PD-L1 CPS ≥1, although a benefit for pembrolizumab emerged with long-term follow-up. Pembrolizumab had a better safety profile than paclitaxel. The pembrolizumab treatment effect was more evident in patients with ECOG PS 0, those with greater PD-L1 expression, and those with MSI-H tumors. Trials of pembrolizumab as monotherapy and as part of combination therapy for G/GEJ cancer are ongoing."

Swiss Expert Statement Article